Spectral to present at Rodman & Renshaw Annual Global Investment Conference on September 10

-Company will also attend World Sepsis Day in New York on September 13-

TORONTO, Sept. 4, 2012 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that Dr. Paul Walker, the Company's President & Chief Executive Officer, is presenting at the Rodman & Renshaw 14th Annual Healthcare Conference. The conference is being held in New York City from September 9-11 at the Waldorf Astoria Hotel.

Dr. Walker will provide a corporate update and participate in a Q&A breakout session on Monday, September 10, 2012 at 3:40 PM ET in the Starlight Center room. Spectral's presentation will be available by webcast at:

http://www.wsw.com/webcast/rrshq22/sdi.to

For additional information on the conference please visit:

http://www.rodmanandrenshaw.com/conferences?id=176

On September 13, 2012, Spectral management will participate in the inaugural World Sepsis Day, in New York. The World Sepsis Day is an initiative of the Global Sepsis Alliance (GSA) and its founding members, all of which are non-profit organizations. The worldwide event is being held to raise the public and professional profile of sepsis - a problem that is common, global in scope, and devastating in its consequences, according to the GSA.

About Spectral Diagnostics
Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA-cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively in more than 100,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, and in November 2010, signed an exclusive distribution agreement for this product in Canada. More than 250,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $1 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol SDI, and on the OTQ QX under the symbol DIAGF. For more information please visit www.spectraldx.com

SOURCE: Spectral Diagnostics Inc.

Anthony Businskas
Executive Vice President and CFO
416-626-3233 ext. 2200

Adam Peeler
Investor Relations
416-815-0700 ext. 225
[email protected]